
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, a bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in Beijing Luzhu Biotechnology Co., Ltd., you should at once hand this circular, together with the enclosed form of proxy, to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



Beijing Luzhu Biotechnology Co., Ltd.
北京綠竹生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2480)

**PROPOSED GENERAL MANDATE TO REPURCHASE H SHARES
AND
NOTICE OF EXTRAORDINARY GENERAL MEETING**

The notice convening the EGM of Beijing Luzhu Biotechnology Co., Ltd. to be held at Conference Room 323, No. 3 Guangtong Street, Industrial Development Zone, Tongzhou District, Beijing, China on Thursday, April 18, 2024 at 10:00 a.m. is set out in this circular and being despatched to the Shareholders.

A proxy form for use at the EGM is enclosed with this circular. Whether or not you intend to attend the EGM, as a holder of H Shares, you are requested to complete the accompanying form of proxy in accordance with the instructions printed thereon and return it to Tricor Investor Services Limited, the H share registrar of the Company in Hong Kong, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong as soon as possible and in any event not later than 24 hours before the time appointed for holding the EGM (i.e. not later than 10:00 a.m. on Wednesday, April 17, 2024 (Hong Kong time)) or any adjournment thereof. Completion and return of the form of proxy will not preclude you from attending and voting in person at the EGM or any adjournment thereof if you so wish.

This circular together with the form of proxy are also published on the websites of Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk) and the Company (www.luzhubiotech.com).

March 26, 2024

CONTENTS

	<i>Page</i>
Definitions	1
Letter from the Board	3
Appendix I – Explanatory Statement	7
Notice of Extraordinary General Meeting	10

DEFINITIONS

In this circular, unless the context otherwise requires, the following expressions shall have the following meanings:

“Articles of Association”	the articles of association of the Company currently in force
“Board”	the board of Directors
“China” or “PRC”	the mainland of the People’s Republic of China, for the purpose of this circular and geographical reference only, excluding Hong Kong, Macau Special Administrative Region and Taiwan
“Company”	Beijing Luzhu Biotechnology Co., Ltd. (北京綠竹生物技術股份有限公司), a joint stock company established in the PRC with limited liability on July 19, 2013, the H Shares of which are listed on the Main Board of the Stock Exchange (stock code: 2480)
“Controlling Shareholders”	has the meaning ascribed to it under the Listing Rules and unless the context otherwise requires refers to Mr. KONG Jian, Ms. Zhang Yanpin and Hengqin Luzhu LP
“Core Product”	has the meaning ascribed to it in Chapter 18A of the Listing Rules and in this context, the Core Product refers to LZ901
“Director(s)”	the director(s) of the Company
“EGM”	the extraordinary general meeting of the Company to be held on Thursday, April 18, 2024 at 10:00 a.m. for the purpose of approving, among other things, the granting of the Repurchase Mandate
“Group”	the Company and its subsidiaries
“H Share(s)”	ordinary share(s) in the share capital of our Company, with a nominal value of RMB1.00 each, which are listed on the Stock Exchange and subscribed for and traded in Hong Kong Dollars
“H Shareholder(s)”	holder(s) of H Shares
“Hengqin Luzhu LP”	Zhuhai Hengqin Luzhu Enterprise Management Partnership (Limited Partnership) (珠海橫琴綠竹企業管理合夥企業(有限合夥)), a limited partnership established in the PRC on January 14, 2021, and an employee incentive platform of the Group

DEFINITIONS

“HK\$” or “Hong Kong Dollars”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Independent Third Party”	a person or entity who is not a connected person of the Company under the Listing Rules
“Latest Practicable Date”	March 22, 2024, being the latest practicable date prior to the printing of this circular for ascertaining certain information in this circular
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange (as amended from time to time)
“LZ901”	the recombinant herpes zoster vaccine candidate of the Group, a herpes zoster vaccine with a tetrameric molecular structure and the Core Product of the Group
“Repurchase Mandate”	a general mandate proposed to be granted to the Board at the EGM to, among others, exercise the power of the Company to repurchase H Shares not exceeding 10.0% of the number of total issued H Shares as of the date of passing of the relevant Shareholders’ resolution granting the Repurchase Mandate
“RMB” or “Renminbi”	Renminbi Yuan, the lawful currency of China
“Share(s)”	ordinary shares of our Company with a nominal value of RMB1.00 each
“Shareholder(s)”	holder(s) of Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Takeovers Code”	The Codes on Takeovers and Mergers and Share Buy-backs issued by the Securities and Futures Commission of Hong Kong (as amended from time to time)
“U.S.”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction

In this circular, the terms “associate”, “close associate”, “connected person”, “core connected person”, “connected transaction”, “subsidiaries” and “substantial shareholder” shall have the meanings given to such terms in the Listing Rules, unless the context otherwise requires.

LETTER FROM THE BOARD



Beijing Luzhu Biotechnology Co., Ltd.
北京綠竹生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2480)

Executive Directors:

Mr. KONG Jian (*Chairman*)
Ms. ZHANG Yanping
Ms. JIANG Xianmin

Non-executive Directors:

Mr. MA Biao
Mr. KONG Shuangquan

Independent Non-executive Directors:

Mr. LEUNG Wai Yip
Mr. LIANG Yeshi
Ms. HOU Aijun

*Registered Office, Headquarters
and Principal Place of
Business in the PRC:*

No. 3 Guangtong Street
Industrial Development Zone
Tongzhou District
Beijing
PRC

*Principal Place of Business in
Hong Kong:*

5/F, Manulife Place
348 Kwun Tong Road
Kowloon
Hong Kong

March 26, 2024

To the Shareholders

Dear Sir/Madam,

**PROPOSED GENERAL MANDATE TO REPURCHASE H SHARES
AND
NOTICE OF EXTRAORDINARY GENERAL MEETING**

1. INTRODUCTION

The purpose of this circular is to give you the notice of the EGM and provide you with the information in respect of the proposed granting of the Repurchase Mandate to the Board to enable you to make a decision on whether to vote for or against the relevant resolution at the EGM.

LETTER FROM THE BOARD

2. GENERAL MANDATE TO REPURCHASE H SHARES

The PRC Company Law (to which the Company is subject) provides that a joint stock limited company incorporated in the PRC may not repurchase its shares except under any of the following circumstances: (a) in order to reduce the registered capital of the company; (b) merger with another company holding shares in the Company; (c) the shares are used for employee stock ownership plan or equity incentives; (d) a shareholder requests the Company to purchase the shares held by him/her since he/she objects to a resolution of the shareholders' meeting on the combination or division of the Company; (e) the shares are used for converting convertible corporate bonds issued by the listed company; or (f) when it is necessary for the listed company to preserve its value and shareholders' rights and interests.

According to the Articles of Association, the Company shall not repurchase its own shares except in any one of the following circumstances: (a) for the reduction of the registered capital of the Company; (b) mergers with other companies holding Shares; (c) using the Shares in employee shareholding scheme or as equity incentive; (d) Shareholders who object to resolutions on the merger or division of the Company at general meeting requesting the Company to repurchase their Shares; (e) using the Shares for conversion of corporate bonds convertible into Shares issued by the Company; and (f) when it is necessary for the Company to preserve its values and the interests of the Shareholders. Further, the Articles of Association also provides that: (a) a reduction of the registered capital of the Company shall be approved by way of special resolution of the Shareholders at general meeting; (b) the registered capital of the Company after reduction shall not be lower than the statutory minimum amount; and (c) for the purpose of reducing its registered capital, the Company shall prepare a balance sheet and an inventory of properties, and notify its creditors within ten days from the resolution to reduce the registered capital and announce it in newspapers within 30 days. A creditor shall have the right to demand the Company to settle its debts or provide a corresponding guarantee within 30 days of receiving such notice from the Company or, in the case of a creditor who has not received any notice, within 45 days of the date of the announcement.

A special resolution will be proposed at the EGM to approve the granting of the Repurchase Mandate to the Board to exercise the powers of the Company to repurchase H Shares representing up to 10.0% of the number of total issued H Shares as of the date of passing of the Shareholders' resolution granting the Repurchase Mandate. The Repurchase Mandate, if approved, will lapse at the earliest of:

- (i) the conclusion of the next annual general meeting of the Company;
- (ii) the expiry of the period within which the next annual general meeting of the Company is required by any applicable law(s) and regulation(s) or the Articles of Association to be held; or
- (iii) revocation or variation of the Repurchase Mandate by ordinary resolution of the Shareholders in general meeting.

LETTER FROM THE BOARD

As of the Latest Practicable Date, there were 202,449,032 H Shares in issue, which also represented the entire issued share capital of the Company. Subject to the passing of the special resolution and on the basis that no further H Shares are issued or repurchased after the Latest Practicable Date and up to the date of the EGM, the Company will be allowed to repurchase a maximum of 20,244,903 H Shares pursuant to the Repurchase Mandate.

An explanatory statement required by the Listing Rules to be sent to the Shareholders in connection with the proposed Repurchase Mandate is set out in Appendix I to this circular. This explanatory statement contains all information reasonably necessary to enable the Shareholders to make an informed decision on whether to vote for or against the relevant resolution at the EGM.

3. NOTICE OF EGM

The notice convening the EGM at Conference Room 323, No. 3 Guangtong Street, Industrial Development Zone, Tongzhou District, Beijing, China on Thursday, April 18, 2024 at 10:00 a.m. is set out on pages 10 to 12 in this circular. In order to ascertain holders of H Shares who are entitled to attend the EGM, the register of members of holders of H Shares of the Company will be closed from Monday, April 15, 2024 to Thursday, April 18, 2024 (both days inclusive). H Shareholders whose names appear on the register of members of the Company on April 18, 2024 are entitled to attend and vote at the EGM. Holders of H Shares who intend to attend the EGM are required to deposit the share certificates together with the transfer documents at the H Share registrar of the Company, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong before 4:30 p.m. on Friday, April 12, 2024.

The proxy form for the EGM is enclosed with this circular. Whether or not you are able to attend the EGM, as a holder of H Shares, you are advised to read the notice of the EGM carefully and to complete the enclosed proxy form in accordance with the instructions printed thereon and return to the H Share registrar of the Company, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, by hand or by post no later than 24 hours before the time appointed for convening the EGM (i.e. not later than 10:00 a.m. on Wednesday, April 17, 2024 (Hong Kong time)) or any adjourned meetings thereof. Completion and return of the proxy form will not preclude you from attending and voting at the EGM or any adjourned meeting(s) thereof in person if you so wish.

4. VOTING BY POLL

Pursuant to Rule 13.39(4) of the Listing Rules, any vote of Shareholders at the EGM must be taken by poll except where the chairman of the meeting decides to allow a resolution solely in respect of a procedural or administrative matter to be voted on by a show of hands. Therefore, the resolution as set out in the notice of the EGM will be voted on by poll. The poll results will be published on the HKEXnews website of Hong Kong Exchanges and Clearing Limited at www.hkexnews.hk and the website of the Company at www.luzhubiotech.com upon the conclusion of the EGM.

LETTER FROM THE BOARD

To the best knowledge of the Company, none of the Shareholders or their respective associates is deemed to have a material interest in the resolution to be proposed at the EGM, and therefore no Shareholder is required to abstain from voting on the resolution.

5. RECOMMENDATION

The Directors consider that the proposed Repurchase Mandate is in the interests of the Group and the Shareholders as a whole and accordingly recommend the Shareholders to vote in favour of the resolution to be proposed at the EGM.

6. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

Yours faithfully,
For and on behalf of the Board
Beijing Luzhu Biotechnology Co., Ltd.
Mr. KONG Jian
Chairman and Executive Director

This Appendix serves as an explanatory statement (“**Explanatory Statement**”) required to be sent to the Shareholders under the Listing Rules in connection with the proposed Repurchase Mandate to be put forward to the EGM.

EXERCISE OF THE REPURCHASE MANDATE

The Board wishes to, through obtaining a general mandate to repurchase H Shares, to repurchase H Shares in the open market at appropriate timing. As of the Latest Practicable Date, there were 202,449,032 H Shares in issue, which also represented the entire issued share capital of the Company. Subject to the passing of the special resolution and on the basis that no further H Shares are issued or repurchased after the Latest Practicable Date and up to the date of the EGM, the Company will be allowed to repurchase a maximum of 20,244,903 H Shares pursuant to the Repurchase Mandate.

REASONS FOR REPURCHASES

The Board considers that the current trading price of the H Shares does not reflect their intrinsic value and the actual business prospects of the Company, in particular taking into account the development progress of LZ901, the Core Product of the Group. Since the listing of the H Shares on May 8, 2023, the Group has completed the Phase II clinical trial of LZ901 in the PRC, and commenced the Phase III clinical trial in the PRC in September 2023. The subject enrollment for the Phase III clinical trial of LZ901 in the PRC was completed in January 2024, with a total of approximately 26,000 healthy subject being enrolled across four provinces in the PRC. In addition, the Group also completed the subject enrollment for the Phase I clinical trial of LZ901 in the U.S. in July 2023.

The Board believes the Repurchase Mandate offers flexibility to the Board, and by repurchasing and subsequently cancelling the repurchased H Shares, depending on the market conditions and funding arrangements at the time, may lead to an enhancement of the net assets of the Company and/or its earnings per H Share. In addition, the repurchase of H Shares can also strengthen the investors’ confidence in the Company and promote a positive effect on maintaining the Company’s reputation in the capital market. In light of the aforesaid, the Board believes that the Repurchase Mandate is in the interests of the Company and the Shareholders as a whole.

FUNDING OF REPURCHASES

The Board considers that the potential repurchase of H Shares shall be funded by its internal resources and/or external financings, to the extent legally permitted to be utilized in this connection. For the avoidance of doubt, the net proceeds from the initial public offering of the H Shares will not be used to carry out the repurchase of H Shares, and any exercise of the Repurchase Mandate, if and when conducted, will be subject to and in compliance with the Articles of Association, the Listing Rules, the Takeovers Code, the laws of the PRC and all applicable laws and regulations to which the Company is subject to.

IMPACT ON THE COMPANY

There might be a material adverse impact on the working capital or gearing position of the Company (as compared with the position disclosed in its most recent published audited accounts for the year ended December 31, 2023) in the event that the Repurchase Mandate is exercised in full. However, the Board does not propose to exercise the Repurchase Mandate to such an extent as would, in the circumstances, have a material adverse effect on the working capital or gearing position, which in the opinion of the Directors are from time to time appropriate for the Company.

DISCLOSURE OF INTERESTS

None of the Directors, and to the best of the knowledge of the Directors, having made all reasonable enquiries, none of their respective close associates, have any present intention, if the Repurchase Mandate is approved by the Shareholders, to sell any H Shares to the Company. No core connected person of the Company has notified the Company that he/she/it has a present intention to sell H Shares to the Company, nor has undertaken not to do so, if the Repurchase Mandate is approved by the Shareholders.

DIRECTORS' CONFIRMATIONS

The Directors confirm that they will exercise the Repurchase Mandate in accordance with the Listing Rules and the applicable laws and regulations of the PRC. The Directors further confirm that neither this Explanatory Statement nor the proposed repurchase of H Shares pursuant to the Repurchase Mandate has any unusual features.

SHARE REPURCHASE MADE BY THE COMPANY

No repurchases of Shares have been made by the Company (whether on the Stock Exchange or otherwise) during the six months immediately preceding the Latest Practicable Date.

TAKEOVERS CODE CONSEQUENCES

If, as a result of a repurchase of H Shares by the Company, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition for the purpose of the Takeovers Code. As a result, a Shareholder or group of Shareholders acting in concert, depending on the level of increase of its or their shareholding, could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with Rule 26 of the Takeovers Code.

As of the Latest Practicable Date, the Controlling Shareholders of the Company, namely Mr. KONG Jian, Ms. ZHANG Yanping and Hengqin Luzhu LP, collectively owned 90,802,013 H Shares, representing approximately 44.85% of the total number of Shares in issue as of the Latest Practicable Date. In the event that the Repurchase Mandate is exercised in full and

assuming that there is no change in (i) the number of Shares held by the Controlling Shareholders, and (ii) the total number of Shares in issue, the shareholding of the Controlling Shareholders will be increased to approximately 49.84% of the reduced total number of Shares in issue immediately after the exercise in full of the Repurchase Mandate. Such exercise of the Repurchase Mandate in full may give rise to an obligation on the Controlling Shareholders to make a mandatory offer under Rule 26 of the Takeovers Code, because they will be regarded as having acquired voting rights exceeding the 2% creeper.

However, the Directors have no present intention to exercise the Repurchase Mandate to repurchase H Shares to the extent that will trigger the obligations under the Takeovers Code to make a mandatory offer. Save as aforesaid, the Directors are not aware of any consequences which would arise under the Takeovers Code as a result of any repurchase of H Shares pursuant to the Repurchase Mandate.

In addition, in exercising the Repurchase Mandate (whether in full or otherwise), the Directors will ensure that the Company shall comply with the requirements of the Listing Rules, including the minimum percentage of Shares being held in public hands.

H SHARES MARKET PRICES

The highest and lowest prices at which the H Shares had been traded on the Stock Exchange during each of the previous 11 months since the listing of the Company and up to the Latest Practicable Date were as follows:

Time	Traded market price	
	Highest (HK\$)	Lowest (HK\$)
2023		
May (listing on May 8, 2023)	31.60	16.14
June	40.00	27.70
July	39.60	29.50
August	42.00	28.20
September	41.00	29.85
October	37.90	31.55
November	39.30	28.75
December	38.20	23.95
2024		
January	31.95	23.95
February	28.80	20.35
March (up to and including the Latest Practicable Date)	24.00	17.00

NOTICE OF EXTRAORDINARY GENERAL MEETING



Beijing Luzhu Biotechnology Co., Ltd. 北京綠竹生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2480)

Notice is hereby given that the extraordinary general meeting of Beijing Luzhu Biotechnology Co., Ltd. (the “**Company**”) will be held at Conference Room 323, No. 3 Guangtong Street, Industrial Development Zone, Tongzhou District, Beijing, China on Thursday, April 18, 2024 at 10:00 a.m. (the “**EGM**”) for the purposes of considering and, if thought fit, passing the following resolution. Unless otherwise indicated, capitalized terms used herein shall have the same meaning as those defined in the circular dated March 26, 2024 issued by the Company (the “**Circular**”):

SPECIAL RESOLUTION

To consider and approve the grant to the Board a general mandate to repurchase the H Shares that:

- (i) subject to paragraph (ii) below, granting of a general mandate to the Board, in compliance with all applicable laws and regulations, the Articles of Association, the Listing Rules, the Takeovers Code, and the requirements of any relevant government or regulatory authority, to exercise all the powers of the Company to repurchase H Shares during the Relevant Period (as defined below);
- (ii) subject to obtaining the approval in paragraph (i) above, the aggregate number of the H Shares to be repurchased by the Company pursuant to the approval in paragraph (i) above during the Relevant Period shall not exceed 10.0% of the total number of issued H shares of the Company as of the date of passing of this resolution;
- (iii) subject to the approval of all relevant government authorities in the PRC for the repurchase of such H Shares being granted, to authorise the Board to:
 - (a) formulate and implement detailed repurchase plan, including but not limited to repurchase price, number of Shares to be repurchased, timing of repurchase and period of repurchase etc.;
 - (b) notify creditors and make announcement in accordance with the requirements of relevant laws, regulations and normative documents as well as the Articles of Association;
 - (c) open overseas share accounts and to carry out related change of foreign exchange registration procedures where necessary;

NOTICE OF EXTRAORDINARY GENERAL MEETING

- (d) carry out relevant approval and filing procedures as required by regulatory authorities and the Stock Exchange;
 - (e) carry out cancellation procedures for repurchased H Shares, reduce the registered capital of the Company, and make corresponding amendments to the Articles of Association relating to total registered capital of the Company and the shareholding structure of the Company etc., and to carry out all necessary statutory registrations and filings;
 - (f) execute, handle or otherwise deal with all other documents and matters relating to, in connection with, or ancillary to the repurchase of H Shares and the corresponding reduction in the registered capital of the Company; and
 - (g) delegate such power as conferred to the Board by this resolution to any person as the Board may think fit;
- (iv) for the purpose of this resolution, “Relevant Period” means the period from the passing of this resolution until whichever is the earliest of:
- (a) the conclusion of the next annual general meeting of the Company;
 - (b) the expiry of the period within which the next annual general meeting of the Company is required by any applicable law(s) and regulation(s) or the Articles of Association to be held; or
 - (c) the passing of an ordinary resolution by the shareholders of the Company in general meeting revoking or varying the authority given to the Board of the Company by this resolution.

For and on behalf of the Board
Beijing Luzhu Biotechnology Co., Ltd.
Mr. KONG Jian
Chairman and Executive Director

Hong Kong, March 26, 2024

NOTICE OF EXTRAORDINARY GENERAL MEETING

Notes:

1. The resolution at the meeting will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). The results of the poll will be published on the websites of Hong Kong Exchanges and Clearing Limited and the Company in accordance with the Listing Rules.
2. Any shareholder of the Company entitled to attend and vote at the meeting is entitled to appoint a proxy/more than one proxy to attend and on a poll, vote instead of him. A proxy need not be a shareholder of the Company. If more than one proxy is appointed, the number of shares in respect of which each such proxy so appointed must be specified in the relevant form of proxy. Every shareholder present in person or by proxy shall be entitled to one vote for each share held by him.
3. In order to be valid, the form of proxy together with the power of attorney or other authority, if any, under which it is signed or a certified copy of that power of attorney or authority, must be deposited at the Company’s H share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong (for holders of H Shares) not less than 24 hours before the time appointed for the meeting (i.e. not later than 10:00 a.m. on Wednesday, April 17, 2024) or the adjourned meeting (as the case may be). Completion and return of the form of proxy shall not preclude a shareholder of the Company from attending and voting in person at the meeting and, in such event, the instrument appointing a proxy shall be deemed to be revoked.
4. For determining the entitlement to attend and vote at the meeting, the register of members of the Company will be closed from Monday, April 15, 2024 to Thursday, April 18, 2024, both dates inclusive, during which period no transfer of shares will be registered. In order to be eligible to attend and vote at the EGM, unregistered holders of shares of the Company shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company’s H share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration not later than 4:30 p.m. on Friday, April 12, 2024.
5. Holders of Shares shall produce their identity documents and supporting documents in respect of the shares of the Company held when attending the EGM. If corporate Shareholders appoints authorized representative to attend the EGM, the authorized representative shall produce his/her identity documents and a notarially certified copy of the relevant authorization instrument signed by the board of directors or other authorized parties of the corporate Shareholders or other notarially certified documents allowed by the Company. Proxies shall produce their identity documents and the proxy forms signed by the Shareholders or their attorneys when attending the EGM.
6. References to time and dates in this notice are to Hong Kong time and dates.